Interventions of Interest: Relyvrio was removed from the market on April 4, 2024. Read ICER’s commentary on Amylyx’s decision to discontinue the drug here. Final Documents ICER’s Chief Medical Officer, David Rind, MD stated: “The votes of the Midwest CEPAC reflected the remaining uncertainties around the benefits of these therapies and the overwhelming certainty that […]
Interventions of Interest: We have deemed this a “special assessment” since this is an early snapshot of emerging agents in the COVID-19 pipeline. December 2022 Update Dominant viral variants, vaccination/prior infection status, and evidence on Paxlovid continue to evolve, but ICER is presenting an update based on recent evidence to help inform new discussions on […]
Interventions of Interest: ICER’s Evidence Report Findings: Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab would achieve common thresholds for cost-effectiveness if priced between $9,000 – $12,100 per year. Recommendations for fair access include ensuring that all biologic options be available for patients with severe […]
Interventions of Interest: The Midwest CEPAC unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel both provide a net health benefit when compared to usual care; despite these benefits, for ide-cel, the only CAR-T agent having received FDA approval at this time, a majority of panelists voted that it represents […]